Assessment of naltrexone in the treatment of schizophrenia
- 1 June 1981
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 74 (1) , 51-53
- https://doi.org/10.1007/bf00431756
Abstract
Naltrexone, a long acting opiate antagonist, and placebo were administered to eight schizophrenics in doses of 200 mg per day for 1 week in a double-blind, crossover design. No improvement was noted, and no side effects resembling the opiate withdrawal syndrome with naltrexone were found. Naltrexone does not appear to alter schizophrenic symptomatology.Keywords
This publication has 18 references indexed in Scilit:
- Isolation of an endogenous compound from the brain with pharmacological properties similar to morphinePublished by Elsevier ,2003
- On the specificity of naloxone as an opiate antagonistLife Sciences, 1979
- Some Observations on the Opiate Peptides and SchizophreniaArchives of General Psychiatry, 1979
- Analeptic and antianaleptic effects of naloxone and naltrexone in rabbitsLife Sciences, 1978
- Effects of Naloxone on Schizophrenia: Reduction in Hallucinations in a Subpopulation of SubjectsScience, 1978
- Intravenous Naloxone Administration in Schizophrenia and Affective IllnessScience, 1977
- Indication of an Antipsychotic Action of the Opiate Antagonist NaloxonePharmacopsychiatry, 1977
- Stereospecific Interaction Between Narcotic Analgesics and a Synaptic Plasma Membrane Fraction of Rat Cerebral CortexActa Pharmacologica et Toxicologica, 1973
- Opiate Receptor: Demonstration in Nervous TissueScience, 1973
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961